Patents by Inventor Martyn Brown

Martyn Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190237765
    Abstract: The present invention relates to an energy storage device comprising a silicate comprises a formula: MvM1wM2xSiyOz where M is selected from the group consisting of Li, Na, K, Al, and Mg M1 is selected from the group consisting of alkaline metals, alkaline earth metals, Ti, Mn, Fe, La, Zr, Ce, Ta, Nb, V and combinations thereof; M2 is selected from the group consisting of B, Al, Ga, Ge or combinations thereof; v, y and z are greater than 0; w and/or x is greater than 0; y?x; and wherein MvM1wM2xSiyOz accounts for at least 90 wt % of the composition.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Martyn BROWN, Richard CLARK, Jason Peter STREET
  • Patent number: 8822475
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: September 2, 2014
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8420643
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: April 16, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8367675
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: February 5, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8258322
    Abstract: An improved process is provided for the synthesis of hexahydrodibenzo[b,d]pyran-9-ones, such as nabilone.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: September 4, 2012
    Assignee: Watson Laboratories, Inc.
    Inventors: Valeriy Mikaylo, Subakar Paramanantham, Ilya Avrutov, Martyn A. Brown, Zemin Li, Natalie Lazarowych
  • Patent number: 8252800
    Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: August 28, 2012
    Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
  • Publication number: 20120077820
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: December 2, 2011
    Publication date: March 29, 2012
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20110281887
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: July 25, 2011
    Publication date: November 17, 2011
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8034815
    Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: October 11, 2011
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20100056811
    Abstract: An improved process is provided for the synthesis of hexahydrodibenzo[b,d]pyran-9-ones, such as nabilone.
    Type: Application
    Filed: August 28, 2009
    Publication date: March 4, 2010
    Inventors: Valeriy Mikaylo, Subakar Paramanantham, Ilya Avrutov, Martyn A. Brown, Zemin Li, Natalie Lazarowych
  • Patent number: 7629347
    Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: December 8, 2009
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, George Ma, Natalie Lazarowych, Stephen Houldsworth, Martyn Brown, Ghenadie Rusu, Jianhua Zhong
  • Publication number: 20090298855
    Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
    Type: Application
    Filed: July 28, 2009
    Publication date: December 3, 2009
    Applicant: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
  • Patent number: 7585866
    Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: September 8, 2009
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
  • Publication number: 20080171744
    Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: January 11, 2008
    Publication date: July 17, 2008
    Applicant: 6441513 CANADA INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20060111371
    Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signalling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.
    Type: Application
    Filed: October 9, 2003
    Publication date: May 25, 2006
    Inventors: Wayne Danter, George Ma, Natalie Lazarowych, Stephen Houldsworth, Martyn Brown, Ghenadie Rusu, Jianhua Zhong
  • Publication number: 20060069105
    Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
    Type: Application
    Filed: July 31, 2003
    Publication date: March 30, 2006
    Inventors: Wayne Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stepehn Houldsworth